Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
Non-Small Cell Lung Cancer
DRUG: RMC-4630|DRUG: Sotorasib
Objective response rate (ORR), ORR as assessed per RECIST v1.1, approximately 12 months
Adverse Events, Number of Participants with Adverse Events, approximately 12 months|Serious Adverse Events, Number of Participants with Serious Adverse Events, approximately 12 months|Vital signs, Number of subjects with clinically significant changes in vital signs, approximately 12 months|Clinical laboratory test values, Number of subjects with clinically significant changes in clinical laboratory test values, approximately 12 months|ECGs Measurements, Number of subjects with clinically significant changes in ECGs Measurements, approximately 12 months|Concentration of RMC-4630, Trough Concentration of RMC-4630, approximately 12 months|Concentration of sotorasib, Trough Concentration of sotorasib, approximately 12 months|Duration of response (DOR), DOR as assessed by RECIST v1.1, approximately 12 months|Disease Control Rate (DCR), DCR as assessed by RECIST v1.1, approximately 12 months|Progression-free survival (PFS), PFS as assessed by RECIST v1.1, approximately 12 months|Overall survival (OS), Overall survival (OS), approximately 12 months
This is a phase 2 multicenter, open-label study evaluating the efficacy, safety, tolerability, and pharmacokinetics (PK) of RMC-4630 in combination with sotorasib in subjects with KRASG12C mutant NSCLC after failure of prior standard therapies.